ACAD
48.6
+1.04
+2.19%
AEMD
10.09
+0.09
+0.90%
APRI
1.56
+0.04
+2.63%
ARNA
4.04
+0.05
+1.25%
ATEC
1.37
0.00
0.00%
CNAT
4.98
+0.08
+1.63%
CRXM
0.26
-0.03
-11.00%
CYTX
0.463
+0.063
+15.7461%
DXCM
82.225
+0.525
+0.643%
GNMK
8.75
-0.35
-3.85%
HALO
23.93
+1.13
+4.96%
ILMN
217.56
+0.29
+0.13%
INNV
0.155
-0.003
-1.899%
INO
7.25
+0.07
+0.97%
ISCO
0.042
-0.006
-12.0000%
ISIS
54.05
+0.37
+0.69%
LGND
106.02
+3.47
+3.38%
LPTN
0.285
+0.005
+1.9286%
MBVX
1.59
-0.01
-0.62%
MEIP
1.57
+0.02
+1.29%
MNOV
3.67
-0.14
-3.67%
MRTX
29.4
+1.16
+4.11%
MSTX
0.46
-0.01
-1.63%
NBIX
51.425
+2.085
+4.2252%
NUVA
49.97
+0.38
+0.77%
ONCS
6.23
+0.2
+3.3184%
ONVO
3.28
-0.1
-2.96%
OREX
4.26
+0.05
+1.19%
OTIC
26.85
-0.13
-0.48%
QDEL
22.115
-0.275
-1.228%
RCPT
227.79
+0.7
+0.31%
RGLS
8.929
+0.249
+2.8721%
RMD
56.63
+1.46
+2.65%
SCIE
0.019
0.00
0.00%
SPHS
0.88
+0.02
+2.33%
SRNE
20.42
-3.28
-13.84%
TROV
8.41
-0.11
-1.29%
VICL
0.635
+0.025
+4.098%
ZGNX
20.29
+0.42
+2.11%
ACAD
48.6
+1.04
+2.19%
AEMD
10.09
+0.09
+0.90%
APRI
1.56
+0.04
+2.63%
ARNA
4.04
+0.05
+1.25%
ATEC
1.37
0.00
0.00%
CNAT
4.98
+0.08
+1.63%
CRXM
0.26
-0.03
-11.00%
CYTX
0.463
+0.063
+15.7461%
DXCM
82.225
+0.525
+0.643%
GNMK
8.75
-0.35
-3.85%
HALO
23.93
+1.13
+4.96%
ILMN
217.56
+0.29
+0.13%
INNV
0.155
-0.003
-1.899%
INO
7.25
+0.07
+0.97%
ISCO
0.042
-0.006
-12.0000%
ISIS
54.05
+0.37
+0.69%
LGND
106.02
+3.47
+3.38%
LPTN
0.285
+0.005
+1.9286%
MBVX
1.59
-0.01
-0.62%
MEIP
1.57
+0.02
+1.29%
MNOV
3.67
-0.14
-3.67%
MRTX
29.4
+1.16
+4.11%
MSTX
0.46
-0.01
-1.63%
NBIX
51.425
+2.085
+4.2252%
NUVA
49.97
+0.38
+0.77%
ONCS
6.23
+0.2
+3.3184%
ONVO
3.28
-0.1
-2.96%
OREX
4.26
+0.05
+1.19%
OTIC
26.85
-0.13
-0.48%
QDEL
22.115
-0.275
-1.228%
RCPT
227.79
+0.7
+0.31%
RGLS
8.929
+0.249
+2.8721%
RMD
56.63
+1.46
+2.65%
SCIE
0.019
0.00
0.00%
SPHS
0.88
+0.02
+2.33%
SRNE
20.42
-3.28
-13.84%
TROV
8.41
-0.11
-1.29%
VICL
0.635
+0.025
+4.098%
ZGNX
20.29
+0.42
+2.11%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.